BioSpace News Archive

The combination of DNA sequencing and whole transcriptome sequencing provides critical insights that can guide treatment decisions across a range of cancers

Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today presented data from the first clinical studies evaluating the oral investigational agents TP-1287, a cyclin-dependent kinase 9 (CDK9) inhibitor, and TP-3654, a PIM kinase inhibitor, in p

Presentations outline how BluePrint® genomic testing enables further categorization of HER2-positive cancer and reclassification of ER+ tumors for patients’ benefit FLEX registry reinforces the clinical and real-world utility of MammaPrint® and BluePrint to improve stratification of breast cancer patients [29-May-2020] IRVINE, Calif. and AMSTERDAM , May 29,

Amgen (NASDAQ:AMGN) today announced new data from the CodeBreaK 100 clinical development program evaluating investigational AMG 510

Agendia, Inc., a world leader in precision oncology for breast cancer, announced new data from MINDACT, the prospective randomized trial designed to further demonstrate the clinical utility of MammaPrint® risk scoring when determining a breast cancer patient’s need for chemotherapy.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced positive d

-- Registrational data in RET fusion-positive NSCLC show 61% ORR in patients previously treated with platinum-based chemotherapy and 73% ORR in treatment-naïve patients -- -- 12% complete response rate in patients with treatment-naïve RET fusion-positive NSCLC -- -- Median DOR not reached across lines of therapy in RET fusion-positive NSCLC, with 6-month DOR of 86% -- -- NDA accepted by FDA and MAA validated by EMA for pralsetinib in RET fusion-positive NSCLC --

-- No complement mediated toxicities and up to 70% clinical benefit¹ across multiple solid tumors -- Combination of AGEN1181 with Agenus’s balstilimab (PD-1) advancing in the clinic -- B. Riley to host conference call with Drs. Steven O’Day and Charles Drake on Next-Generation CTLA-4 agents - June 2, 2020 [29-May-2020] LEXINGTON, Mass. , May 29, 202

COTA, Inc., a healthcare technology company that uses real-world data (RWD) to bring clarity to cancer care, is pleased to announce its involvement and participation in two indus

Across all groups combined, complete responses (CR) are now 16%; in the metastatic group with the longest follow-up CRs are 20%, nearly tripling with two additional years of follow-up Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Sanofi today announced new, longer-term data for PD-1 inhibitor Libtayo ® (cem